Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer
Read More
News
All
- Neumora in the News
- Press Releases
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
Read More
Boston Business Journal: Amgen-partnered neuroscience startup rakes in another $112M
Read More
BioPharma Dive: Brain disease startup Neumora draws more funding for ambitious research plan
Read More
Endpoints: The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies
Read More
The Economist: Better brain biology will deliver better medicines
Read More
Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University
Read More
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
Read More
Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
Read More
STAT: Backed with $500 million, a startup aims to rethink psychiatric drug development
Read More
Endpoints: ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more
Read More
Business Insider: A new startup created by one of biotech’s biggest VCs shows you need to go big to treat brain disorders
Read More
Biopharma Dive: Armed with half a billion dollars, a startup aims to change how brain drugs are made
Read More
Timmerman Report: Neumora Secures $500M, Amgen Deal, in Quest for Neuroscience R&D
Read More
BioCentury: Arch-backed Neumora: using data tools for precision neuroscience
Read More
Boston Globe: Neumora hopes to bring precision medicine to brain disease treatments
Read More
Boston Business Journal: Psychiatric drug startup launches with $500M, Amgen partnership
Read More
Chemical & Engineering News: Neumora launches with $500 million to develop drugs for brain diseases
Read More
FierceBiotech: Meet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D
Read More
Daily Mail: Amgen to invest $100 million in SoftBank-backed Neumora
Read More